
ProQR Therapeutics (PRQR) Stock Forecast & Price Target
ProQR Therapeutics (PRQR) Analyst Ratings
Bulls say
ProQR Therapeutics NV is positioned favorably due to the potential acceleration of its pipeline products into clinical trials, which could enhance stock appreciation by yielding proof of concept data sooner than previously anticipated. The company’s Axiomer RNA base-editing platform is viewed as a promising asset, with upcoming clinical data from its first-in-human study expected to significantly impact its valuation. Additionally, ProQR's strong cash position is projected to sustain its operational needs through mid-2027, providing a solid foundation for ongoing research and development efforts.
Bears say
ProQR Therapeutics reported a significant increase in net loss for the quarter, reaching -€12.2 million with a corresponding EPS of (€0.12), a stark contrast to the previous year's loss of -€2.7 million and EPS of (€0.03). This widening loss may raise concerns regarding the company's financial health and operational efficiency. Additionally, the potential for competitive therapeutic options to emerge, combined with reliance on the outcomes of uncertain Phase Ib/II/III studies, contributes to a negative outlook on the stock as future profitability remains uncertain.
This aggregate rating is based on analysts' research of ProQR Therapeutics and is not a guaranteed prediction by Public.com or investment advice.
ProQR Therapeutics (PRQR) Analyst Forecast & Price Prediction
Start investing in ProQR Therapeutics (PRQR)
Order type
Buy in
Order amount
Est. shares
0 shares